AZD7442 PhIII trial positive in COVID outpatients
11 October 2021 07:00 BST AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Trial met primary endpoint AZD7442 is the only long-acting antibody combination shown to both prevent and treat COVID-19 Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca's AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19. A